496 related articles for article (PubMed ID: 24528892)
1. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia.
Lindstrom ST; Wong EK
Intern Med J; 2014 Apr; 44(4):390-7. PubMed ID: 24528892
[TBL] [Abstract][Full Text] [Related]
2. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia.
Long W; Deng X; Zhang Y; Lu G; Xie J; Tang J
Respirology; 2011 Jul; 16(5):819-24. PubMed ID: 21507143
[TBL] [Abstract][Full Text] [Related]
3. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia.
Esposito S; Tagliabue C; Picciolli I; Semino M; Sabatini C; Consolo S; Bosis S; Pinzani R; Principi N
Respir Med; 2011 Dec; 105(12):1939-45. PubMed ID: 21959024
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia.
Claessens YE; Mathevon T; Kierzek G; Grabar S; Jegou D; Batard E; Loyer C; Davido A; Hausfater P; Robert H; Lavagna-Perez L; Bernot B; Plaisance P; Leroy C; Renaud B
Intensive Care Med; 2010 May; 36(5):799-809. PubMed ID: 20232049
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia.
Kasamatsu Y; Yamaguchi T; Kawaguchi T; Tanaka N; Oka H; Nakamura T; Yamagami K; Yoshioka K; Imanishi M
Respirology; 2012 Feb; 17(2):330-6. PubMed ID: 22059525
[TBL] [Abstract][Full Text] [Related]
6. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
Ugajin M; Yamaki K; Hirasawa N; Yagi T
Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
[TBL] [Abstract][Full Text] [Related]
7. Improved management of community-acquired pneumonia in the emergency department.
Julián-Jiménez A; Palomo de los Reyes MJ; Parejo Miguez R; Laín-Terés N; Cuena-Boy R; Lozano-Ancín A
Arch Bronconeumol; 2013 Jun; 49(6):230-40. PubMed ID: 23477946
[TBL] [Abstract][Full Text] [Related]
8. The value of procalcitonin level in community-acquired pneumonia in the ED.
Park JH; Wee JH; Choi SP; Oh SH
Am J Emerg Med; 2012 Sep; 30(7):1248-54. PubMed ID: 22030193
[TBL] [Abstract][Full Text] [Related]
9. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers and community-acquired pneumonia: tailoring management with biological data.
Torres A; Ramirez P; Montull B; Menéndez R
Semin Respir Crit Care Med; 2012 Jun; 33(3):266-71. PubMed ID: 22718212
[TBL] [Abstract][Full Text] [Related]
11. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia.
Schuetz P; Litke A; Albrich WC; Mueller B
Curr Opin Infect Dis; 2013 Apr; 26(2):159-67. PubMed ID: 23434895
[TBL] [Abstract][Full Text] [Related]
12. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?
Pereira JM; Teixeira-Pinto A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
J Crit Care; 2013 Dec; 28(6):970-4. PubMed ID: 24216331
[TBL] [Abstract][Full Text] [Related]
13. The role of procalcitonin in adult patients with community-acquired pneumonia--a systematic review.
Berg P; Lindhardt BØ
Dan Med J; 2012 Mar; 59(3):A4357. PubMed ID: 22381083
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.
Masiá M; Gutiérrez F; Shum C; Padilla S; Navarro JC; Flores E; Hernández I
Chest; 2005 Oct; 128(4):2223-9. PubMed ID: 16236878
[TBL] [Abstract][Full Text] [Related]
15. Procalcitonin levels in community-acquired pneumonia - correlation with aetiology and severity.
Johansson N; Kalin M; Backman-Johansson C; Larsson A; Nilsson K; Hedlund J
Scand J Infect Dis; 2014 Nov; 46(11):787-91. PubMed ID: 25195651
[TBL] [Abstract][Full Text] [Related]
16. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia.
Perren A; Cerutti B; Lepori M; Senn V; Capelli B; Duchini F; Domenighetti G
Infection; 2008 Mar; 36(2):163-6. PubMed ID: 18330505
[TBL] [Abstract][Full Text] [Related]
17. [The value of serum procalcitonin in treatment of community acquired pneumonia in outpatient].
Long W; Deng XQ; Tang JG; Xie J; Zhang YC; Zhang Y; Gao YY; Lu G
Zhonghua Nei Ke Za Zhi; 2009 Mar; 48(3):216-9. PubMed ID: 19576090
[TBL] [Abstract][Full Text] [Related]
18. Procalcitonin kinetics in Legionella pneumophila pneumonia.
de Jager CP; de Wit NC; Weers-Pothoff G; van der Poll T; Wever PC
Clin Microbiol Infect; 2009 Nov; 15(11):1020-5. PubMed ID: 19438643
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of procalcitonin in community-acquired pneumonia.
Schuetz P; Suter-Widmer I; Chaudri A; Christ-Crain M; Zimmerli W; Mueller B;
Eur Respir J; 2011 Feb; 37(2):384-92. PubMed ID: 20595156
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic value of serum procalcitonin in identifying the etiology of non-responding community-acquired pneumonia after initial antibiotic therapy].
Wang Z; Zhang X; Wu J; Zhang W; Kuang H; Li X; Xuan W; Wang K; Ma L
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Nov; 37(11):824-30. PubMed ID: 25604112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
